Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4614 | 9002-92-0 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
An alkyl polyglycol ether of LAURYL ALCOHOL, chemically defined as an alcohol ethoxylate having an average alkyl chain of 12–14 carbon atoms, and an ethylene oxide chain of 9 ethylene oxide units. It is used as a detergent, and medically as a local anesthetic, and as a sclerosing agent for the treatment of ESOPHAGEAL AND GASTRIC VARICES and VARICOSE VEINS.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| March 30, 2010 | FDA | CHEMISCH FBRK KRSSLR |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Deep vein thrombosis | 357.98 | 57.05 | 90 | 573 | 91530 | 90536254 |
| Peripheral vein thrombus extension | 148.99 | 57.05 | 14 | 649 | 3 | 90627781 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Deep vein thrombosis | 150.07 | 71.32 | 46 | 341 | 76911 | 42544037 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Deep vein thrombosis | 255.61 | 48.90 | 76 | 737 | 139811 | 110448675 |
| Peripheral vein thrombus extension | 127.26 | 48.90 | 12 | 801 | 3 | 110588483 |
None
| Source | Code | Description |
|---|---|---|
| ATC | C05BB02 | CARDIOVASCULAR SYSTEM VASOPROTECTIVES ANTIVARICOSE THERAPY Sclerosing agents for local injection |
| FDA PE | N0000009905 | Vascular Sclerosing Activity |
| FDA MoA | N0000020024 | Sclerosing Activity |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D003902 | Detergents |
| MeSH PA | D012597 | Sclerosing Solutions |
| MeSH PA | D013501 | Surface-Active Agents |
| FDA EPC | N0000175814 | Sclerosing Agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:38828 | nonionic surfactant |
| CHEBI has role | CHEBI:50908 | hepatotoxic agent |
| CHEBI has role | CHEBI:63923 | sclerotherapy agent |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Venous varices | indication | 128060009 | DOID:799 |
None
None
None
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 180MG/18ML (10MG/ML) | VARITHENA | BOSTON SCITFC | N205098 | Nov. 25, 2013 | RX | SOLUTION | INTRAVENOUS | 7814943 | Nov. 19, 2027 | A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE |
None
None
| ID | Source |
|---|---|
| D01993 | KEGG_DRUG |
| 4031333 | VUID |
| N0000184324 | NUI |
| 4031333 | VANDF |
| CHEBI:46859 | CHEBI |
| CHEMBL6067961 | ChEMBL_ID |
| 1562 | INN_ID |
| DB06811 | DRUGBANK_ID |
| 0AWH8BFG9A | UNII |
| 1484399 | RXNORM |
| 185389 | MMSL |
| 21617 | MMSL |
| 229664 | MMSL |
| d05824 | MMSL |
| 006261 | NDDF |
| 013940 | NDDF |
| 427905004 | SNOMEDCT_US |
| 427906003 | SNOMEDCT_US |
| C0071330 | UMLSCUI |
| D000077423 | MESH_DESCRIPTOR_UI |
| 656641 | PUBCHEM_CID |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Asclera | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67850-140 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | NDA | 26 sections |
| Asclera | HUMAN PRESCRIPTION DRUG LABEL | 1 | 67850-141 | INJECTION, SOLUTION | 0.01 g | INTRAVENOUS | NDA | 26 sections |